JV-394 / UT MD Anderson Cancer Center - LARVOL DELTA

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Natural Killer/T-cell Lymphoma • Oncology • CD8 • KLRD1